Form 4/A for INMB Inmune Bio, Inc.
Accepted 2024-04-24 00:00:00 ET · period of report 2024-04-19 · accession 0001213900-24-035723 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DA | 2024-04-24 | 2024-04-19 | INMB | Moss David J | CFO, Treas, Sec, 10% | P - Purchase | $8.32 | +18.0K | 1.27M | +1% | +$150.0K |
| DA | 2024-04-24 | 2024-04-19 | INMB | Moss David J | CFO, Treas, Sec, 10% | P - Purchase | $0.13 | +18.0K | 18.0K | New | +$2,344 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-04-19 | P | A | 18,028 | $8.32 | 1,268,179 | D | — | — | (F1) The common shares and warrants reported on this Form 4 were purchased in a registered direct offering at a price of $8.445, for an aggregate purchase price of $152,246.46 pursuant to a securities purchase agreement dated April 19, 2024. The warrants are exercisable immediately upon issuance until the earlier of (i) the two year anniversary of the initial exercise date or (ii) thirty trading days following the reporting of the top line data (EMACC) in the Phase 2 Alzheimer's program of XPro1595, (the "Termination Date") but not thereafter, provided however, in the event that the Warrant is held by directors, officers or other affiliates of the Company and the Termination Date is during a period that such officers, directors or affiliates are subject to a blackout with respect to trading in the Company's common stock, such officers, directors or affiliates will have an additional 60 days from the termination of the blackout date to exercise the Warrant. |
| 2 | Derivative | Common Stock Warrants (right to buy) | 2024-04-19 | P | A | 18,028 | $0.13 | 18,028 | D | $9.15 · 2024-04-24 to — | 18,028 Common Stock | (F1) The common shares and warrants reported on this Form 4 were purchased in a registered direct offering at a price of $8.445, for an aggregate purchase price of $152,246.46 pursuant to a securities purchase agreement dated April 19, 2024. The warrants are exercisable immediately upon issuance until the earlier of (i) the two year anniversary of the initial exercise date or (ii) thirty trading days following the reporting of the top line data (EMACC) in the Phase 2 Alzheimer's program of XPro1595, (the "Termination Date") but not thereafter, provided however, in the event that the Warrant is held by directors, officers or other affiliates of the Company and the Termination Date is during a period that such officers, directors or affiliates are subject to a blackout with respect to trading in the Company's common stock, such officers, directors or affiliates will have an additional 60 days from the termination of the blackout date to exercise the Warrant. |